Picture loading failed.

Pre-Made Gantenerumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-232-1mg 1mg 3090
GMP-Bios-ab-232-10mg 10mg Inquiry
GMP-Bios-ab-232-100mg 100mg Inquiry
GMP-Bios-ab-232-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Gantenerumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
INN Name Gantenerumab
TargetAPP
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5csz:HL:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2008
CompaniesMorphoSys;Chugai Pharmaceutical;Roche
Conditions Approvedna
Conditions ActiveAlzheimer's disease
Conditions Discontinuedna
Development Techna